Colorectal

The A.R.CA.D colorectal cancer program is based on an international database of 63 therapeutic clinical trials on metastatic colorectal cancer (mCRC). It brings together around 50,000 individual data on patients, diseases, treatments and results.

The colorectal database (mCRC) was created in 2007 to improve the management and evaluation of drugs for patients with metastatic colorectal cancer, and ultimately improve and accelerate regulatory approvals.

In 2020, the Foundation partnered with the National Cancer Center Hospital East (Kashiwa, Japan). The Mayo Clinic (Rochester, Minnesota, United States) worked on improving the base data management since 2023.

The analyzes carried out by statisticians based in France, the United States and Japan on the mCRC database aim to demonstrate and standardize new criteria for evaluating the effectiveness of treatments.

The A.R.CA.D colorectal program is opened to all centers across the world, whether private or public. Investigators are requested to include all their operated patients consecutively and to provide their follow-up on a long-term basis.

Conditions to integrate the ARCAD Colorectal Group

The ARCAD Colorectal Group is a diverse group, including world-renowned scientists who are experts in their field: oncologists, researchers, and statisticians.

To join the Group, one of the 2 following conditions must be filled:

to be involved in the steering committee of a published phase 3 or phase 2 randomized clinical trial and to help to the transfer of one or multiple trials on colorectal cancer to the database
to be a renowned scientist (oncologist, radiotherapist, surgeon, statistician) invited by the Steering Committee as member to join the Group in relation with help and work for the ARCAD colorectal database.

There is no formal membership to participate in the ARCAD colorectal database project. The PIs of each trial or a selected collaborator are invited to join the group.

For any further information, please contact us